Filing Analysis
Quoin Pharmaceuticals, Ltd. announced its first quarter 2026 financial results on May 7, 2026. The filing serves as a formal notice of the earnings release, with the detailed financial data contained in the attached press release exhibit.
Key Facts
- The filing was made on May 7, 2026, reporting results for the first quarter of 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- Quoin Pharmaceuticals is an Israeli-incorporated company with principal executive offices in Ashburn, VA.
- The company's American Depositary Shares (ADS) each represent thirty-five (35) Ordinary Shares.
Quoin Pharmaceuticals, Ltd. announced its financial results for the fourth quarter and fiscal year ended 2025. The filing includes a press release detailing the company's financial performance and operational status as of March 26, 2026.
Key Facts
- The company reported Q4 and full-year 2025 financial results on March 26, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- A press release was included as Exhibit 99.1.
- The registrant is an Israeli-incorporated company with American Depositary Shares (ADSs) listed on Nasdaq (QNRX).
Quoin Pharmaceuticals announced that the FDA has granted Fast Track Designation to its lead candidate, QRX003 lotion (4%), for the treatment of Netherton Syndrome. This designation is intended to expedite the development and review process for therapies addressing serious conditions with unmet medical needs.
Key Facts
- On March 11, 2026, the FDA granted Fast Track Designation to QRX003 lotion (4%).
- The target indication is Netherton Syndrome, a rare and severe genetic skin disorder with no currently approved treatments.
- Fast Track benefits include more frequent FDA interactions, eligibility for rolling review, and potential qualification for Accelerated Approval and Priority Review.
- The announcement was made via a press release furnished under Item 7.01 and Item 8.01.